国际血管与腔内血管大会 / VEITH 2024
纽约时间2024年11月19-23日，国际血管与腔内血管大会（VEITH Symposium 2024）在美国纽约顺利举行。会议期间，血管资讯特邀中山大学附属第一医院姚陈教授进行了独家专访，姚陈教授聚焦于VEITH会上主动脉领域内的创新亮点、内脏动脉重建的新技术以及VEITH会议中值得国内借鉴的特色版块展开分享。精彩内容整理如下，欢迎阅读与分享！
Q1
本次VEITH会上有哪些主动脉领域内的创新值得深入关注？
▲点击播放视频
中国技术获国际认可：VEITH会议上，中国专家展示的自主研发主动脉支架技术受到国际同行广泛认可。
国际创新与中国展望：国际上在升主动脉和冠脉重建领域有创新进展，中国需关注并推动自主研发技术走向国际舞台。
Q2
在内脏动脉重建领域中，有哪些新技术新疗法？
▲点击播放视频
内脏区重建技术进展：内脏区重建技术经历了从杂交手术到平行支架，再到医生现场改装支架的发展，目前正朝着更微创、更有效的产品化分支支架方向发展。
未来临床应用展望：自主研发的产品化分支支架被视为未来全腔内治疗内脏区重建的最终解决方案，期待其早日广泛应用于临床。
Q3
VEITH会议中哪些议题与特色板块值得国内会议借鉴？
▲点击播放视频
顶尖诊所经验分享：会议中的一个亮点是顶尖诊所分享他们的经营和管理理念，这些新颖的设计和经验对国内会议具有借鉴价值。
| 议程名称 | 演讲者 |
| A Tribute To Hans-HenningEckstein,MD,PhD(1955-2024) | Sebastian E. Debus, MD, PhD |
| Einstein And Nissen: A New York Story About An AAA Wrapped In Cellophane | Frank J. Criado, MD |
| The SVS Digital History Archive: What ls it, Why lt ls lmportant And Should Vascular SurgeonsContribute To lt And Use lt | Jerry Goldstone, MD, FACS, FRCSEd |
| Multispecialty Vascular Care Departments Or Units Within institutions Are Best For Patients AndPhysicians: How Should The Dominant Specialty And Leader Be Chosen: How Should Rewards Be Distributed | Samuel R. Money, MD, MBA / Barry T. Katzen, MD |
| Vascular Surgery's ldentity And Role ls Usually In A Subservient Position Within A Heart And VascularUnit: What Should Be Done To Correct This inequity in The interest Of Better Patient Care | Timur P Sarac, MD |
| Vascular Surgery Needs An Independent ABMs Approved Board And Associated RRC To Thrive As A Specialty In The Medical Hierarchy And To Have lts Value Appropriately Recognized | Sean P Lyden,MD |
| The Negative lmpact Of Hospital Administrators On Vascular Surgery And Vascular Surgeons' Careers:Why ls lt Happening, Why ls it Worse For Vascular Surgeons Than Other Specialists And What Can Be Done To Counteract lt | Samuel R. Money, MD, MBA |
| The Role Of Women in Vascular Surgery: What Has it Been And Where ls it Going | Cynthia k. Shortell, MD |
| Simultaneous Overuse And Undertreatment Of Patients With PAD And CLTl: Why The Problem ExistsAnd What Should Be Done To Fix lt | Joseph L. Mills,MD |
| Physician And Industry Responsibility In Overuse Of Technology (Atherectomy, CAS, EVAR, Etc.):Especially lmportant In View Of The Recent Media Spotlight On This lssue | Murray L. Shames, MD |
| Why Vascular Surgeons Should Unionize: The Pros And Cons | Enrico Ascher, MD |
| Racial And Ethnic Disparities in Clinical Trials And The Treatment Of CLTl: What Are The Causes AndWhat Can Be Done About Them | Vincent L. Rowe,MD |
| What's Happening With Vascular Surgeon Reimbursement in 2024 And What Are The Prospects For 2025: For Hospital And OBL Procedures | Sean P Roddy, MD |
| Current Medicare Reimbursement For Ch/EVAR And F/EVAR ls inadequate: The Situation ls Untenable:How Did We Get There And Can The Problem Be Fixed | Clayton J. Brinster, MD |
| Reimbursement For Vascular Procedures Under CMS ls Deeply Flawed And Subject To The Bias Of Others: lt Results In Unethical Compensatory Behavior: What Can Be Done About it | Sean P Roddy, MD |
| New Developments In And Benefits From VQl Participation: it Will Make For Better Doctors AndVascular Care And it Will Cut Hospital Costs | Jens Eldrup-Jorgensen, MD |
| The SVS/ACs Vascular Verification Program (VVP) To Assure Quality Vascular Care in inpatient AndOutpatient Programs: What is lt And How Will lt Help Vascular Surgery | Anton N. Sidawy, MD |
| How Can The Insurance Industry lmprove The Quality And Appropriateness Of Vascular Care And HelpVascular Surgery Survive In A Competitive World | Russell H, Samson, MD, DFSVS, RVT, FACS |
| How Do We Hold Physicians Who Provide False Or Misleading Testimony Against Vascular SurgeonsAccountable: Has The SVs Committee On This Topic Ever Done Anything To Do What Should Be Done | O,william Brown, MD |
| Our System Of Peer Reviews ls Flawed: Within Hospitals; Within Journal Reviews: How Might ArtificialIntelligence (Al) lmprove Them | Timothy M. Sullivan, MD |
| What ls An lmpact Factor For A Peer Reviewed Journal Or An Article: What ls Plum X And H-index: How Are They Calculated And Why Are They lmportant: What Constitutes Plagiarism - it's Not Simple | Peter F Lawrence, MD/Peter Gloviczki. MD |
| I Was From The Government And i'm Here To Help: FDA Resources :To Assure Safe And Effective MedicalDevices in Vascular Disease: What ls The LEAF Initiative To Assure That Trials Are Appropriate For FDA Approval | Robert E. Lee, MD/ Philip P Goodney, MD, MS |
| Why Do lDEs Fail To Get FDA Approval: Updates To The FDA 510 (K) Program And Why They Are Important | Valerie M. Merkle, PhD |
| Different Perspectives From industry And The FDA Regarding The lmportance Of innovation.Engineering And Financial Rewards That Influence Innovation | Dorothy B. Abel, BSBME |
| What ls A Learning Health System And Why Should lt Matter To Vascular Surgery | Charles c. Miller PhD |
Session 36 链接：https://www.veithsymposium.org/current/session_detail.php?ref=41
Session 38 链接：https://www.veithsymposium.org/current/session_detail.php?ref=43
政策影响与临床实践：会议讨论了未来政策变化对临床决策的影响，强调了对集采后DRG等政策的解读和临床实践调整的重要性。
姚陈 教授
中山大学附属第一医院
版权声明：本平台旨在帮助医疗卫生专业人士更好地了解相关疾病领域最新进展。本平台对发布的资讯内容，并不代表同意其描述和观点，仅为提供更多信息。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。仅供医疗卫生专业人士为了解资讯使用，该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解资讯以外的目的，本平台及作者不承担相关责任。合作联系邮箱：vascular@edoctor.work。
